Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

26.7%

4 terminated/withdrawn out of 15 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

60%

9 trials in Phase 3/4

Results Transparency

80%

8 of 10 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

Phase 3

9(60.0%)

Phase 2

4(26.7%)

Phase 1

2(13.3%)

15Total

Phase 3(9)

Phase 2(4)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT06050122Phase 3Active Not Recruiting

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

Role: lead

NCT04308395Phase 3Terminated

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

Role: lead

NCT03703310Phase 3Completed

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

Role: lead

NCT04155190Phase 2Terminated

An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Role: lead

NCT05675501Phase 1Completed

Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties

Role: lead

NCT03761810Phase 3Completed

A Study of S6G5T3 in the Treatment of Acne Vulgaris

Role: lead

NCT03761784Phase 3Completed

A Study of S6G5T-3 in the Treatment of Acne Vulgaris

Role: lead

NCT03564119Phase 3Completed

A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea